Sign In
Buy MLTX
$18.27
+0.400 (+2.24%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
New York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
MLTX Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 18, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
5AM Venture Bails on MoonLake After a Brutal Year: Here's What Stands Out
01:55pm, Tuesday, 18'th Nov 2025
Sold 282,313 shares for an estimated $13.33 million net change Post-sale, the fund holds zero shares valued at $0 The position was previously 5.12% of the fund's assets as of last quarter
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 18'th Nov 2025
BENSALEM, Pa. , Nov. 18, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities Violations - Contact Levi & Korsinsky Today
09:04am, Tuesday, 18'th Nov 2025
New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the f
NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLAS
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
08:50am, Tuesday, 18'th Nov 2025
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) fo
SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D
MoonLake: Ignore The Panic, Catch The Upside
12:33am, Tuesday, 18'th Nov 2025
MoonLake Immunotherapeutics is rated Buy, with sonelokimab having multiple dermatology and rheumatology indications. MLTX's VELA-1 trial succeeded, and VELA-2's statistical miss was due to elevated pl
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
09:45pm, Monday, 17'th Nov 2025
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 202
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) bet
New York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
SAN FRANCISCO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
12:47pm, Monday, 17'th Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquire
